Vision-Related Functioning Outcomes of Dexamethasone Intravitreal Implant in Noninfectious Intermediate or Posterior Uveitis

• Autor(a) principal: Lightman, Susan
• Data de Publicação: 2013
• Outros Autores: Belfort, Rubens Junior [UNIFESP], Naik, Rupali K., Lowder, Careen, Foster, C. Stephen, Rentz, Anne M., Cui, Harry, Whitcup, Scott M., Kowalski, Jonathan W., Revicki, Dennis A.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1167/iovs.12-10981; http://repositorio.unifesp.br/handle/11600/36453
• topic: dexamethasone intravitreal implant; quality of life; treatment outcomes

PURPOSE. To evaluate the effect of a single treatment with dexamethasone intravitreal implant (DEX implant) on patient-reported visual functioning in patients with noninfectious intermediate or posterior uveitis.METHODS. Patient eyes with noninfectious intermediate or posterior uveitis were randomized to a single treatment with DEX implant 0.70 mg (n = 77), DEX implant 0.35 mg (n = 76), or a sham procedure (n = 76) and followed for 26 weeks. Vision-related functioning was measured using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) assessed at baseline and at weeks 8, 16, and 26 or early exit. Analysis of covariance and mixed model analysis of covariance were used to compare vision-related functioning between the DEX implant 0.70 and 0.35 mg groups and the sham group.RESULTS. By 8 weeks, the DEX implant 0.70 mg group demonstrated significant improvements in NEI VFQ-25 subscales near vision (P = 0.031), distance vision (P = 0.023), peripheral vision (P = 0.045), vision-specific social functioning (P = 0.019), and the NEI VFQ-25 composite score (P = 0.007) compared with sham. After 26 weeks, the DEX implant 0.70 mg group reported significant improvements in NEI VFQ-25 subscales distance vision (P = 0.003), vision-specific role difficulties (P = 0.038), vision-specific dependency (P = 0.017), vision-specific social functioning (P = 0.009), vision-specific mental health (P = 0.036), and the composite score (P = 0.001) compared with sham.CONCLUSIONS. in patients with noninfectious intermediate or posterior uveitis receiving a single treatment of DEX implant 0.70 mg, significant and clinically meaningful improvements in patient-reported visual functioning were observed as early as week 8 and were maintained over 26 weeks. (ClinicalTrials.gov number, NCT00333814.)